SLC5A2 and chronic kidney disease: Health care professionals may be hesitant to prescribe SGLT2 inhibitors to patients with CKD at a lower risk of progression, such as patients with albuminuria and preserved eGFR or those with impaired kidney function and low urinary albumin-creatinine ratio (UACR), owing to limited evidence from clinical trials in these patient groups.